Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | F7 | P08709 | 3/20 | 0.36 |
| ▸ | F3 | P13726 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22838309 | 1.00 | TRPV1 (0.36) | TRPV1ALDH1A1F7F3KDM4E | |
| SCHEMBL22838284 | 0.99 | TRPV1 (0.36) | TRPV1ALDH1A1F7F3KDM4E | |
| SCHEMBL28391207 | 0.96 | FAAH (0.35) | TRPV1ALDH1A1F7F3PPARG | |
| SCHEMBL20018225 | 0.95 | ALOX5 (0.35) | TRPV1 | |
| SCHEMBL21235415 | 0.90 | FAAH (0.33) | ALDH1A1F7F3KDM4EPPARG | |
| SCHEMBL21235414 | 0.89 | TRPV1 (0.32) | TRPV1 | |
| SCHEMBL13778820 | 0.87 | TRPV1 (0.35) | TRPV1ALDH1A1F7F3KDM4E | |
| SCHEMBL19882101 | 0.87 | CNR1 (0.35) | TRPV1ALDH1A1F7F3KDM4E | |
| SCHEMBL2332115 | 0.87 | CNR1 (0.35) | TRPV1ALDH1A1F7F3KDM4E | |
| SCHEMBL12216913 | 0.86 | TRPV1 (0.40) | TRPV1ALDH1A1F7F3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 553 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358652-A1 | LIPID NANOPARTICLE FORMULATIONS | MONASH UNIVERSITY (AU) | 2024-10-31 | — | — | US | claimed |
| EP-4387657-A1 | LIPID NANOPARTICLE FORMULATIONS | Monash University (AU) | 2024-06-26 | — | — | EP | claimed |
| WO-2023019310-A1 | LIPID NANOPARTICLE FORMULATIONS | MONASH UNIVERSITY (AU) | 2023-02-23 | — | — | WO | claimed |
| WO-2022115739-A1 | — | — | 2022-06-02 | — | — | WO | claimed |
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2019-11-07 | — | — | US | claimed |
| EP-3468608-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac AG (DE) | 2019-04-17 | — | — | EP | claimed |
| EP-3468612-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac AG (DE) | 2019-04-17 | — | — | EP | claimed |
| WO-2017212006-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2017-12-14 | — | — | WO | claimed |
| WO-2017212008-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CUREVAC AG (DE) | 2017-12-14 | — | — | WO | claimed |
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIV OF PENNSYLVANIA (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026102245-A1 | MICROFLUIDIC MIXING DEVICES FOR HIGH-THROUGHPUT LIPID NANOPARTICLE (LNP) PREPARATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | FLAGSHIP LABS 114, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4495237-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2026-05-13 | — | — | EP | disclosed |
| US-20100130588-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| WO-2010054401-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054401-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010042877-A1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009127060-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129319-A2 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | LCP2, CD47, CD4 | TRPV1 1316/4885ALDH1A1 2851/4885F7 3502/4885 |
| US-20260130860-A1 | LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS | NSUN3, NSUN2, LDLR | TRPV1 3541/4885ALDH1A1 4164/4885F7 3240/4885 |
| US-20240358652-A1 | LIPID NANOPARTICLE FORMULATIONS | LIPA, LIPC, PHOSPHO1 | TRPV1 1651/4885ALDH1A1 1747/4885F7 1361/4885 |
| US-20100130588-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | SARNP, NPC1L1, SNRPE | TRPV1 4728/4885ALDH1A1 2566/4885F7 3906/4885 |
| US-20190336611-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | PHAX, LNPEP, PITPNB | TRPV1 2515/4885ALDH1A1 4507/4885F7 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.